Sterile manufacturing3 min readBy QLogixCMC
Annex 1 three years on: the contamination control strategy inspectors now read first
A contamination control strategy (CCS) is the document, required by the revised EU GMP Annex 1 since August 2023, that sets out how a sterile manufacturing site keeps microbial, pyrogen and particulate contamination out of its products: every control, from facility design and gowning to sterilization, aseptic process simulation and environmental monitoring, with the reasoning that connects them and the data that shows they work. Three years on, inspectors ask for it first, and the gap they find most is not a missing control but a missing connection between the controls and the data.
What the revised annex changed
- A documented contamination control strategy for the site, maintained and reviewed, that links the controls to the risks they address
- Quality risk management as the basis for the design of the facility, the process and the monitoring, with the assessments on file
- Environmental and personnel monitoring with alert and action levels, trended, and reviewed as part of the CCS rather than as a stand-alone log
- Aseptic process simulation, sterilization and barrier technology expectations written out in more detail, and the same expectations applied to advanced therapies made aseptically
- Explicit attention to the people in the cleanroom: qualification, gowning, behaviour and the frequency of their monitoring
Where inspections find the gaps
- A CCS that lists procedures without saying which contamination risk each one controls, or what evidence shows it works
- Environmental monitoring reviewed sample by sample against action levels, with no trend that would show a slow drift
- Alert and action levels copied from the annex's tables rather than set from the site's own data
- Interventions in the aseptic process that are performed but not represented in the process simulation
- A CCS written once for the inspection and not updated after changes, deviations or monitoring excursions
Trending is the part that pays
Action levels catch a bad day. A contamination recovery rate, the share of samples showing growth in a period, trended against a limit set from the site's own baseline, catches a bad month: a gowning change that did not take, a disinfectant rotation that stopped, an air handling unit losing capacity. The annex asks for both, and the second is where a site learns something before a batch is at risk.
Interactive
Catching a contamination shift: action levels or the trend?
6weeks earlier from the trend
The trend crosses its limit in week 23; the first action-level excursion comes in week 29. Every batch in between was made in an area already drifting.
- Weekly recovery rate
- 6-week trend
- Trend limit from baseline
- First action-level excursion
How QLogixCMC helps
QLogixCMC writes or remediates the contamination control strategy from the site's risk assessments and data, sets alert and action levels and trend limits from the baseline, designs the environmental monitoring program and its review, prepares the aseptic process simulation protocol, and runs mock inspections that read the CCS the way an inspector does. The site's qualified people own the strategy and sign every limit.
Questions this post answers
What has to be in a contamination control strategy?
The controls the site relies on to keep microbial, pyrogen and particulate contamination out of its products, the risks each control addresses, the monitoring that shows the controls work, and the process for reviewing and updating the strategy. Annex 1 lists the elements it expects to see covered, from facility design and utilities to personnel, process, sterilization and monitoring.
How are alert and action levels set?
From the site's own monitoring data, reviewed periodically, within the maximum limits the annex sets per grade. A level copied from the annex's table is a ceiling, not a site's alert level; a level set from the baseline is what makes a trend meaningful.
Does Annex 1 apply to US sites?
Directly only to products made for the EU market and to sites inspected by EU authorities. In practice its expectations, in particular the contamination control strategy, are read alongside FDA's aseptic processing guidance, and FDA inspectors ask similar questions of the same controls.